By Deena Beasley and Julie Steenhuysen SAN FRANCISCO (Reuters) - Japan's Eisai Co plans to seek full approval of its experimental Alzheimer's drug lec.
The drug significantly improved memory and other factors in patients when compared to a placebo, and more details about the study will be released in November.
Shares of Biogen and other drugmakers researching Alzheimer’s disease soared Wednesday after Japan’s Eisai Co. said its potential treatment appeared to slow the fatal disease in a late-stage study. The drugmaker said early results showed that its treatment, lecanemab, reduced patient clinical decline by 27% when compared to a placebo or fake drug after 18…